Melanoma Clinical Trial
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease
Summary
The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment (Study S187.3.003 [NCT00360568] or Study S187.3.004 [NCT00335153]).
Eligibility Criteria
Inclusion Criteria:
The participant should have completed participation in Study S187.3.003 or S187.3.004; and, in the opinion of the Principal Investigator, would benefit from long-term treatment with LCIG.
For Canada, participants will be allowed to participate in the S187.3.005 study with a minimum of 6 months of exposure to LCIG in the S187.3.004 study.
The participant must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study related procedures. If the participant does not have the capacity to provide informed consent, full informed consent must be obtained from the participant's legally authorized representative. Consenting will be performed according to local regulations.
Exclusion Criteria:
Medical, laboratory, psychiatric, or surgical issues deemed by the investigator to be clinically significant and which could interfere with the participant's participation in the study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 61 Locations for this study
Birmingham Alabama, 35294, United States
Encinitas California, 92024, United States
Fountain Valley California, 92708, United States
Los Angeles California, 90033, United States
Englewood Colorado, 80113, United States
Washington District of Columbia, 20007, United States
Bradenton Florida, 34205, United States
Fort Lauderdale Florida, 33308, United States
Gainesville Florida, 32610, United States
Jacksonville Florida, 32209, United States
Port Charlotte Florida, 33980, United States
Tampa Florida, 33612, United States
Augusta Georgia, 30912, United States
Chicago Illinois, 60611, United States
Chicago Illinois, 60612, United States
Lexington Kentucky, 40536, United States
Shreveport Louisiana, 71130, United States
Baltimore Maryland, 21201, United States
Baltimore Maryland, 21287, United States
Saint Louis Missouri, 63110, United States
Omaha Nebraska, 68198, United States
Manhasset New York, 11030, United States
New York New York, 10029, United States
New York New York, 10032, United States
Raleigh North Carolina, 27607, United States
Winston-Salem North Carolina, 27157, United States
Cincinnati Ohio, 45267, United States
Cleveland Ohio, 44195, United States
Burlington Vermont, 05401, United States
Kirkland Washington, 98034, United States
Milwaukee Wisconsin, 53226, United States
Westmead New South Wales, 2145, Australia
Adelaide South Australia, 5000, Australia
Heidelberg Victoria, 3084, Australia
Edmonton Alberta, T6G 2, Canada
Toronto Ontario, M5T 2, Canada
Montréal Quebec, H2X 0, Canada
Brno , 656 9, Czechia
Hradec Králové , 500 0, Czechia
Pardubice , 532 0, Czechia
Praha , 128 2, Czechia
Praha , 150 0, Czechia
Tel-Aviv , 64239, Israel
Hamilton Waikato, 3240, New Zealand
Auckland , 1023, New Zealand
Christchurch , 8011, New Zealand
Wellington , 6021, New Zealand
Åódź Lodzkie, 93-11, Poland
Poznań Wielkopolskie, 61-48, Poland
Coimbra , 3000-, Portugal
Lisboa , 1649-, Portugal
Porto , 4200-, Portugal
Kazan , 42009, Russian Federation
Moscow , 12536, Russian Federation
Saint Petersburg , 19404, Russian Federation
Saint Petersburg , 19702, Russian Federation
Saint Petersburg , 19770, Russian Federation
Bangkok , 10330, Thailand
Bangkok , 10700, Thailand
Liverpool , L9 7L, United Kingdom
London , WC1N , United Kingdom
How clear is this clinincal trial information?